Patients were divided into four groups: untreated FMF patients consisting of recently diagnosed patients who are not yet placed on colchicine, “stable FMF” treated with colchicine with well controlled disease, “unstable FMF” treated with colchicine and showing persistent symptoms, and MEFV mutation carriers. This evidence concerns the gene MEFV and familial Mediterranean fever.